Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides

The toxic effects of various concentrations of 2',3'-dideoxycytidine (ddC), 2',3'-dideoxy-2',3'-didehydrothymidine (D4T), and 2',3'-dideoxyinosine (ddI) on CEM cells after 4 days of culture were assessed by measuring cell viability, mitochondrial DNA (mtDNA) content, and mitochondrial morphology. Cell viability and mtDNA content in drug-treated cultures were significantly reduced in a concentration-dependent fashion in comparison with cell viability and mtDNA content in untreated cultures. Cells in the treated cultures also showed significant changes in their mitochondrial morphologies which included distortion and reduction of the cristae and numerous vesicles. Unique features of the morphological changes were associated with each drug. The decrease in cell viability and mtDNA content and the increase in mitochondrial ultrastructural changes were directly related to the concentrations of the drugs used. The potencies of these compounds in reducing cell viability, mtDNA content, and normal mitochondria were in the order ddC > D4T > ddI. Comparison of the three assays used demonstrated that mtDNA content is a significantly more sensitive measure of drug toxicity than cell viability and mitochondrial morphology for the three compounds studied.

[1]  L. Lewis,et al.  Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine , 1992, Antimicrobial Agents and Chemotherapy.

[2]  R. N. Brogden,et al.  Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. , 1992, Drugs.

[3]  C. H. Chen,et al.  Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. , 1991, Molecular pharmacology.

[4]  M. Dalakas,et al.  Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.

[5]  M. Dalakas,et al.  Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′‐dideoxycytidine (ddc) , 1989, Muscle & nerve.

[6]  H. Mitsuya,et al.  In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. , 1989, Science.

[7]  C. H. Chen,et al.  Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. , 1989, The Journal of biological chemistry.

[8]  H. Mitsuya,et al.  PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT) , 1988, The Lancet.

[9]  J. Meldolesi,et al.  Subcellular redistribution of lysosomal enzymes during caerulein-induced pancreatitis. , 1987, The American journal of physiology.

[10]  M A Fischl,et al.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[11]  N. Bresolin,et al.  Peripheral neuropathy in mitochondrial disease , 1987, Journal of the Neurological Sciences.

[12]  H. Mitsuya,et al.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. Haynes,et al.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. , 1984, Science.

[14]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[15]  M. Steer,et al.  Effects of ethionine on digestive enzyme synthesis and discharge by mouse pancreas. , 1980, The American journal of physiology.

[16]  G. Godman,et al.  RESPIRATORY ENZYMES AND MITOCHONDRIAL MORPHOLOGY OF HELA AND L CELLS TREATED WITH CHLORAMPHENICOL AND ETHIDIUM BROMIDE , 1972, The Journal of cell biology.

[17]  S. Steinberg,et al.  2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. , 1993, The Journal of infectious diseases.

[18]  S. Mellgren,et al.  Early mitochondrial changes in chronic progressive ocular myopathy. , 1990, European neurology.

[19]  F. N. Ghadially,et al.  Chloramphenicol-induced mitochondrial and ultrastructural changes in hemopoietic cells. , 1976, Archives of pathology & laboratory medicine.